The Transformation of CML Treatment and Care
Topic Areas:
Chronic Myelogenous Leukemia
View next
Published on September 15, 2017
Have there been new developments in chronic myelogenous leukemia (CML) treatment and care? Expert, Dr. Michael Deininger from Huntsman Cancer Institute at the University of Utah, discusses ongoing research, treatment side effect management, and the results of a 10-year study on survival rates and imatinib (Gleevec). Dr. Deininger also sheds light on the accessibility of certain medicines, the importance of molecular testing, and how clinical trials show doctors and patients what is possible for the future of treatment.
